As previously reported, Argus analyst John Eade downgraded IFF to Hold from Buy. The firm remains positive on the company’s innovative products and expects synergies and cross-selling opportunities from recent acquisitions, but also sees its growth trajectory being negatively impacted by higher costs for raw materials and transportation, supply-chain disruptions, volume slowdowns and geopolitical developments, the analyst tells investors in a research note. Argus adds it would move the stock back to Buy if earnings growth jumps from low single-digits to high single-digits.
Confident Investing Starts Here:
- Quickly and easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on IFF:
- Wolfe starts IFF at Underperform, says valuation in line with higher-end product
- IFF initiated with an Underperform at Wolfe Research
- IFF reports approval of SYNERXIA yeasts in Argentina for biofuel production
- IFF price target raised to $83 from $82 at Mizuho
- IFF price target raised to $90 from $85 at Wells Fargo